Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

An exasperated Copperfield on the trials and tribulations that Mounjaro prescribing has wreaked on general practice ...

Eli Lilly and Company (LLY), one of the world’s leading pharmaceutical giants, might have just unveiled its next major growth catalyst — one that could significantly bolster its dominant position in ...

A chip addict who ballooned to 280 pounds scoffing down four bags a day managed to lose half her body weight naturally — ...

Several studies have found patients taking GLP-1 medications like Wegovy and Mounjaro regain weight, sparking fresh health advice from experts.

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

A daily pill that works like Ozempic can help slimmers lose an average of two stone, trials have found. The study of ...

Lilly's stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook. A previous report had an incorrect company name.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...